Staphylococcus aureus, methicillin sensitive (2018 Data)
Antibiotic |
% Susceptible |
Antibiotic |
% Susceptible |
|
Ampicillin | - |
Imipenem | + |
|
Azithromycin | + |
Levofloxacin | 77 |
|
Aztreonam | - |
Meropenem | + |
|
Cefazolin | 100 |
Moxifloxacin | 96
|
|
Cefepime | + |
Nitrofurantoin | 99&
|
|
Ceftazidime | +/- |
Oxacillin/Naf | 100 |
|
Ceftriaxone | 100 |
Penicillin | 0 |
|
Cefuroxime | + |
Piperacillin | -
|
|
Ciprofloxacin | 76 |
Piperacillin/tazo | + |
|
Clarithromycin | + |
Ticarcillin/Clav | + |
|
Clindamycin | 86 |
Tobramycin | + |
|
Doxycycline | 94 |
TMP/SMX | 100 |
|
Erythromycin | 63 |
Unasyn/Aug | 100 |
|
Gentamicin | + |
Vancomycin | 100 |
|
Number of isolates tested: 1241
Comments: Fluoroquinolone use as first line agents against Staph aureus is discouraged.
For historical susceptibility data click here
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections